Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Descripción del proyecto

Unos nuevos fármacos que vencen la resistencia a los antibióticos podrían llegar a los ensayos clínicos

Las bacterias gram negativas poseen una membrana exterior que evita que penetren los antibióticos. El aumento de la multirresistencia en las bacterias gram negativas se está convirtiendo en un gran desafío para la salud pública y el proyecto GNA NOW, financiado con fondos europeos, se ha creado para afrontarlo. Como parte del nuevo Programa de la Unión Europea Antimicrobial Resistance Accelerator, expertos del mundo académico y de la industria prevén descubrir y probar los compuestos antibióticos más prometedores a lo largo de los próximos seis años y llevar algunos de ellos a la fase de ensayo clínico.

Objetivo

AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.

Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

STICHTING LYGATURE
Aportación neta de la UEn
€ 757 556,25
Dirección
JAARBEURSPLEIN 6
3521 AL Utrecht
Países Bajos

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
West-Nederland Zuid-Holland Agglomeratie ’s-Gravenhage
Tipo de actividad
Other
Enlaces
Coste total
€ 757 556,25

Participantes (12)